Company profile

Guardant Health

Guardant Health, founded in 2012 by AmirAli Talasaz, has raised $557M across private and public financings, including a $360M Series E in 2017 and later IPO placements. The company develops liquid biopsy technologies, enabling tumor DNA sequencing from blood for precision oncology, therapy selection, and clinical trial matching. Funding supported R&D, clinical validation, commercial scaling, and pharma partnerships. Employing around 1,351 people, Guardant Health accelerates adoption of non-invasive genomic testing. Investors include Lightspeed Venture Partners, Sequoia Capital, SoftBank Vision Fund, OrbiMed, and Khosla Ventures, positioning the company as a leader in oncology diagnostics and liquid biopsy innovation.

Back to profiles

Quick facts

Total funding: $557M
Founded: 2012

Notable investors

Lightspeed Venture Partners
Sequoia Capital
SoftBank Vision Fund
OrbiMed
Khosla Ventures

Reach buyers like Guardant Health on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Guardant Health
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Guardant Health.

The 14-day trial ships every feature, no card required.

Start free →